JP2010047612A5 - - Google Patents

Download PDF

Info

Publication number
JP2010047612A5
JP2010047612A5 JP2009272270A JP2009272270A JP2010047612A5 JP 2010047612 A5 JP2010047612 A5 JP 2010047612A5 JP 2009272270 A JP2009272270 A JP 2009272270A JP 2009272270 A JP2009272270 A JP 2009272270A JP 2010047612 A5 JP2010047612 A5 JP 2010047612A5
Authority
JP
Japan
Prior art keywords
nateglinide
preparation according
tablet
preparation
per tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009272270A
Other languages
English (en)
Other versions
JP5282722B2 (ja
JP2010047612A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2009272270A priority Critical patent/JP5282722B2/ja
Priority claimed from JP2009272270A external-priority patent/JP5282722B2/ja
Publication of JP2010047612A publication Critical patent/JP2010047612A/ja
Publication of JP2010047612A5 publication Critical patent/JP2010047612A5/ja
Application granted granted Critical
Publication of JP5282722B2 publication Critical patent/JP5282722B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (10)

  1. ナテグリニドを有効成分として含有する経口投与用製剤において、ナテグリニドを製剤総重量に対して２６％以上、及びカルボキシメチルスターチナトリウム、クロスカルメロースナトリウム、部分アルファー化デンプン及び低置換度ヒドロキシプロピルセルロースからなる群から選ばれる崩壊剤の少なくとも一つを製剤総重量に対して２８％以上含有することを特徴とする前記製剤。
  2. 前記経口投与用製剤が錠剤の形態であって、かつ一錠当たりのナテグリニド含有量が６０ｍｇ以上である請求項１記載の製剤。
  3. 崩壊剤が、カルボキシメチルスターチナトリウム、カルメロースカルシウム及びカルメロースカリウムからなる群から選ばれる少なくとも１つである請求項１記載の製剤。
  4. 更に酸性化剤を含む請求項１乃至３のいずれか１項記載の製剤。
  5. 酸性化剤を製剤総重量に対して５％以上含有する請求項４記載の製剤。
  6. 更に湿潤剤を含む請求項５記載の製剤。
  7. 湿潤剤が界面活性剤又は無水二酸化珪素である請求項６記載の製剤。
  8. 錠剤当たり、５０質量％以上のナテグリニド及び３０質量％以上のカルボキシメチルスターチナトリウム、クロスカルメロースナトリウム、部分アルファー化デンプン及び低置換度ヒドロキシプロピルセルロースからなる群から選ばれる崩壊剤の少なくとも一つを含有するナテグリニド含有錠剤。
  9. 一錠当たりのナテグリニド量が６０ｍｇ以上であり、全質量が１００〜２５０ｍｇである、請求項８記載のナテグリニド含有錠剤。
  10. 一錠当たりのナテグリニド量が９０ｍｇであり、全質量が１３０〜１８０ｍｇである、請求項８記載のナテグリニド含有錠剤。
JP2009272270A 2003-08-08 2009-11-30 ナテグリニド含有製剤 Expired - Fee Related JP5282722B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009272270A JP5282722B2 (ja) 2003-08-08 2009-11-30 ナテグリニド含有製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003290464 2003-08-08
JP2003290464 2003-08-08
JP2009272270A JP5282722B2 (ja) 2003-08-08 2009-11-30 ナテグリニド含有製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005513036A Division JP4505859B2 (ja) 2003-08-08 2004-08-09 ナテグリニド含有製剤

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011222076A Division JP4947820B2 (ja) 2003-08-08 2011-10-06 ナテグリニド含有製剤
JP2012236421A Division JP5557169B2 (ja) 2003-08-08 2012-10-26 ナテグリニド含有製剤

Publications (3)

Publication Number Publication Date
JP2010047612A JP2010047612A (ja) 2010-03-04
JP2010047612A5 true JP2010047612A5 (ja) 2012-01-05
JP5282722B2 JP5282722B2 (ja) 2013-09-04

Family

ID=34131587

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2005513036A Expired - Lifetime JP4505859B2 (ja) 2003-08-08 2004-08-09 ナテグリニド含有製剤
JP2008265459A Expired - Fee Related JP4995798B2 (ja) 2003-08-08 2008-10-14 ナテグリニド含有製剤
JP2009272270A Expired - Fee Related JP5282722B2 (ja) 2003-08-08 2009-11-30 ナテグリニド含有製剤
JP2011222076A Expired - Lifetime JP4947820B2 (ja) 2003-08-08 2011-10-06 ナテグリニド含有製剤
JP2012236421A Expired - Lifetime JP5557169B2 (ja) 2003-08-08 2012-10-26 ナテグリニド含有製剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2005513036A Expired - Lifetime JP4505859B2 (ja) 2003-08-08 2004-08-09 ナテグリニド含有製剤
JP2008265459A Expired - Fee Related JP4995798B2 (ja) 2003-08-08 2008-10-14 ナテグリニド含有製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011222076A Expired - Lifetime JP4947820B2 (ja) 2003-08-08 2011-10-06 ナテグリニド含有製剤
JP2012236421A Expired - Lifetime JP5557169B2 (ja) 2003-08-08 2012-10-26 ナテグリニド含有製剤

Country Status (4)

Country Link
US (1) US7732492B2 (ja)
JP (5) JP4505859B2 (ja)
KR (2) KR100882156B1 (ja)
WO (1) WO2005013964A1 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4501054B2 (ja) * 2000-10-24 2010-07-14 味の素株式会社 ナテグリニド含有製剤
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
CN101420937B (zh) 2006-04-12 2011-06-22 日本曹达株式会社 缓释性片剂的制造方法
US10741034B2 (en) 2006-05-19 2020-08-11 Apdn (B.V.I.) Inc. Security system and method of marking an inventory item and/or person in the vicinity
US9790538B2 (en) 2013-03-07 2017-10-17 Apdn (B.V.I.) Inc. Alkaline activation for immobilization of DNA taggants
EP2100608A4 (en) * 2006-12-07 2009-12-09 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING A SOLID PREPARATION
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
KR101665705B1 (ko) * 2006-12-07 2016-10-12 다이이찌 산쿄 가부시키가이샤 안정성이 개선된 필름 코팅 제제
CN101600430A (zh) * 2006-12-07 2009-12-09 第一三共株式会社 含有甘露糖醇或乳糖的固体药物制剂
WO2008136392A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. 経口投与用製剤
TR200801178A2 (tr) * 2008-02-22 2009-09-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Nateglinid ve surfaktan-ph ayarlayıcı sistemi içeren oral tablet kompozisyonları
SI2407166T1 (sl) * 2009-03-13 2013-12-31 Toyama Chemical Co., Ltd. Tableta in granuliran praĺ ek, vsebujoäśa 6-fluoro-3-hidroksi-2-pirazinkarboksamid
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
ES2768349T3 (es) 2010-03-29 2020-06-22 Ea Pharma Co Ltd Preparación farmacéutica que comprende un derivado de fenilalanina
WO2013066278A1 (en) * 2011-11-03 2013-05-10 Mahmut Bilgic A process for production of pharmaceutical formulations comprising nateglinide
WO2013115739A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Production method for formulations comprising comprising nateglinide and lipoic acid
US20150174075A2 (en) 2012-03-29 2015-06-25 Daicel Corporation Method for producing disintegrating particulate composition comprising acid-type carboxymethylcellulose, disintegrating particulate composition comprising acid-type carboxymethylcellulose, and orally disintegrating tablet including disintegrating particulate composition comprising acid-type carboxymethylcellulose
US9266370B2 (en) 2012-10-10 2016-02-23 Apdn (B.V.I) Inc. DNA marking of previously undistinguished items for traceability
US9297032B2 (en) * 2012-10-10 2016-03-29 Apdn (B.V.I.) Inc. Use of perturbants to facilitate incorporation and recovery of taggants from polymerized coatings
US9963740B2 (en) 2013-03-07 2018-05-08 APDN (B.V.I.), Inc. Method and device for marking articles
WO2015046219A1 (ja) * 2013-09-27 2015-04-02 株式会社ダイセル 崩壊性粒子組成物を含む口腔内崩壊錠剤
CA2926436A1 (en) 2013-10-07 2015-04-16 Judith Murrah Multimode image and spectral reader
US10745825B2 (en) 2014-03-18 2020-08-18 Apdn (B.V.I.) Inc. Encrypted optical markers for security applications
US10047282B2 (en) 2014-03-18 2018-08-14 Apdn (B.V.I.) Inc. Encrypted optical markers for security applications
US10760182B2 (en) 2014-12-16 2020-09-01 Apdn (B.V.I.) Inc. Method and device for marking fibrous materials
WO2017180302A1 (en) 2016-04-11 2017-10-19 Apdn (B.V.I.) Inc. Method of marking cellulosic products
US10995371B2 (en) 2016-10-13 2021-05-04 Apdn (B.V.I.) Inc. Composition and method of DNA marking elastomeric material
US10920274B2 (en) 2017-02-21 2021-02-16 Apdn (B.V.I.) Inc. Nucleic acid coated submicron particles for authentication

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2259646C2 (de) * 1972-12-06 1984-11-22 Hoechst Ag, 6230 Frankfurt Hochdosierte Tabletten von Cephalosporin-Derivaten sowie Verfahren zu ihrer Herstellung
JPS5438167B2 (ja) * 1974-04-27 1979-11-19
JPS5344618A (en) * 1976-10-04 1978-04-21 Takeda Chem Ind Ltd Preparation of tablet
ATE13486T1 (de) * 1980-11-12 1985-06-15 Ciba Geigy Ag Schnellzerfallende arzneimittel-presslinge.
WO1987005804A1 (en) * 1986-04-01 1987-10-08 The Upjohn Company Methylprednisolone/sodium carboxymethyl starch tablet composition
JPH0415221A (ja) 1990-05-08 1992-01-20 Daicel Chem Ind Ltd ポリカーボネートの製造法
JPH09208468A (ja) * 1996-02-02 1997-08-12 Dainippon Pharmaceut Co Ltd ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤
EA001089B1 (ru) 1996-02-29 2000-10-30 Фудзисава Фармасьютикал Ко., Лтд. ТАБЛЕТКИ, СОДЕРЖАЩИЕ β-ЛАКТАМНЫЙ АНТИБИОТИК, И СПОСОБ ИХ ИЗГОТОВЛЕНИЯ
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
NZ333301A (en) * 1996-07-01 1999-09-29 Pfizer Virginiamycin, sodium lauryl sulphate and colloidal silicon dioxide composition
DK1586314T3 (da) 1996-11-15 2011-06-20 Ajinomoto Kk Nateglinide tablet sammensætning
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
JP2945001B1 (ja) * 1997-09-10 1999-09-06 大日本製薬株式会社 カーボン１３尿素含有錠
DK1100469T3 (da) * 1998-07-28 2005-04-18 Takeda Pharmaceutical Hurtigt henfaldende fast præparat
JP2000178184A (ja) * 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
JP2000351732A (ja) * 1999-06-07 2000-12-19 Taisho Pharm Ind Ltd 水分散性良好なアシクロビル含有錠剤
EP1200091B1 (en) * 1999-08-03 2008-07-02 Lilly Icos LLC Pharmaceutical composition comprising tadalafil
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
IL150204A0 (en) 1999-12-23 2002-12-01 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
MXPA02006443A (es) 1999-12-28 2002-11-29 Ajinomoto Kk Preparaciones orales para diabetes.
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
AU2001285768B2 (en) * 2000-06-22 2005-03-10 Novartis Ag Solid valsartan pharmaceutical compositions
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
AU2001288102A1 (en) 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
JP4501054B2 (ja) 2000-10-24 2010-07-14 味の素株式会社 ナテグリニド含有製剤
PT1334721E (pt) 2000-10-24 2009-06-01 Ajinomoto Kk Preparações de fármacos hidrofílicos contendo nateglinida
JP4370050B2 (ja) * 2000-12-04 2009-11-25 大正製薬株式会社 クラリスロマイシン錠剤およびその製造法
JP2002326925A (ja) * 2001-04-27 2002-11-15 Asahi Breweries Ltd 造粒物および錠剤の製造方法
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
JP4029926B2 (ja) * 2002-01-25 2008-01-09 サンウエーブ工業株式会社 回転式載置台
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
CN1557291A (zh) 2004-01-14 2004-12-29 杨喜鸿 那格列奈分散片及其制备方法
WO2005094812A1 (ja) 2004-04-01 2005-10-13 Ajinomoto Co., Inc. ナテグリニド含有製剤
JP2008265459A (ja) 2007-04-18 2008-11-06 Daihatsu Motor Co Ltd アクスルハウジング

Similar Documents

Publication Publication Date Title
JP2010047612A5 (ja)
JP2011037832A5 (ja)
NO20084992L (no) Farmasoytisk produkt for intraoral avlevering av nikotin innbefattende trometamol som bufringsmiddel
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
HRP20211752T1 (hr) Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
ECSP088240A (es) Composición de trazodona para administración una vez por día
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
JP2010132654A5 (ja)
NO20083151L (no) Fast dispersjon omfattende en aktiv bestanddel med et lavt smeltepunkt, og tablett for oral administrering omfattende samme
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
JP2010520246A5 (ja)
MX2009011554A (es) Preparacion solida estable conteniendo un derivado de 4,5-epoximorfinano.
JP2010527347A5 (ja)
JP2011506587A5 (ja)
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
JP2014221827A5 (ja)
RU2014137096A (ru) Перорально вводимая фармацевтическая композиция
JP2018039810A5 (ja)
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
HRP20100120T1 (hr) Formulacije s valsartanom
JP2006342148A5 (ja)
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
NO20090262L (no) Galeniske formuleringer av aliskiren og hydroklorotiazid
JP2015129124A5 (ja)
TWI351957B (en) Prolonged-release diuretic compositions